A micro-cap pharmaceutical stock soared 19 percent after reporting an extraordinary 1,570 percent quarter-on-quarter increase in net profit, signaling a significant turnaround and robust profitability. The company also recorded strong revenue growth during the same period, further underscoring its improving financial health and operational momentum.
With a market capitalization of Rs.1,009 crores, the shares of Wanbury Ltd reached an intra-day high of Rs.329.70 per share on Friday, rising 18.8 percent from its previous day’s closing price of Rs.277.56 apiece.
Financial Performance
Wanbury Ltd experienced a significant rise fueled by strong net profit and revenue growth, as reflected in its latest financial results. In Q4 FY25, the company reported revenue of Rs.173.84 crore, up 23.88 percent from Rs.140.33 crore in Q4 FY24. On a sequential basis, revenue increased by 29.47 percent compared to Rs.134.28 crore in Q3 FY25, indicating strong operational momentum.
The net profit for the quarter stood at Rs.20.25 crore, declining 39.78 percent from Rs.33.63 crore in the same quarter last year. However, net profit surged by 1,573.55 percent from Rs.1.21 crore in Q3 FY25, reflecting a substantial improvement over the previous quarter.
For the full year FY25, the company posted revenue of Rs.603.00 crore, a 4.21 percent increase over Rs.578.63 crore in FY24. The net profit declined by 45.44 percent to Rs.30.53 crore from Rs.55.95 crore in the prior fiscal year.
Wanbury Limited is a mid-sized pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) with a presence spanning several years. It offers over 13 API products and is the largest manufacturer of Metformin in India, producing more than 8,500 tons annually. Wanbury exports to over 70 countries, with 65 percent of sales in regulated markets. The company operates two US FDA-approved multi-product API facilities, highlighting its focus on quality and compliance.
Wanbury Ltd completed a US FDA inspection at its Patalganga facility in Maharashtra with zero Form 483 observations. The inspection took place from June 10 to June 14, 2024. The company exports APIs to over 70 countries, including the US and Europe, and reported a revenue of Rs.575.6 crore in FY24, marking a 15.2 percent year-on-year growth.
Written by – Siddesh S Raskar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
